Dynavax Technologies

424 articles with Dynavax Technologies

• Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany

  5/27/2021

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany

• Dynavax to Present at the William Blair 41st Annual Growth Stock Conference

  5/19/2021

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the William Blair 41th Annual Growth Stock Conference on Tuesday, June 1, 2021 at 2:40 p.m. C.T.

• Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering

  5/11/2021

  Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933

• Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

  5/10/2021

   Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2026 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers

• Dynavax Announces First Quarter 2021 Financial Results

  5/6/2021

  Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the first quarter of 2021.

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021

  5/4/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares of Dynavax common stock as inducements to seven newly-hired employees in connection with commencement of employment with the Company.

• Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

  4/22/2021

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021 , after the U.S. financial markets close.

• Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant

  4/6/2021

  VLA2001, an inactivated COVID-19 vaccine candidate with CpG 1018 adjuvant, was highly immunogenic and generally safe and well tolerated

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 02, 2021

  4/2/2021

  Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 142,000 shares of Dynavax common stock as inducements to six newly-hired employees in connection with commencement of employment with the Company.

• Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

  3/24/2021

  Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA across Latin America, Asia, Europe and Africa

• Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

  3/1/2021

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021 .

• Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2021

  3/1/2021

  Dynavax Technologies Corporation reported that in connection with the commencement of Ms. MacDonald's employment with the Company as Senior Vice President and Chief Financial Officer on March 1, 2021, the Company granted her a non-statutory stock option to purchase 350,000 shares of Dynavax common stock.

• Dynavax to Present at the Cowen 41st Annual Health Care Conference

  2/16/2021

  Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the Cowen 41st Annual Health Care Conference on Monday, March 1 , at 3:20 p.m. E.T.

• Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018

  2/4/2021

  - Tdap vaccine adjuvanted with CpG 1018 is focused on addressing rising incidence of pertussis since the change to acellular vaccines in the 1990s - CpG 1018 adjuvant has the potential to increase durability of the immune responses to pertussis and reduce transmission in previously vaccinated asymptomatic individuals

• 

  2021 Biopharma Update on the Novel Coronavirus: February 2

  2/2/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.

• Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government

  2/1/2021

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has informed it that the UK Government exercised its option to order an additional 40 million doses of Valneva's SARS-CoV-2 adjuvanted vaccine candidate,

• Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

  2/1/2021

  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations  (CEPI) today announced they have entered into an agreement to support the supply of Dynavax's CpG 1018

• Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate - Feb 01, 2021

  2/1/2021

  Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

• Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

  2/1/2021

  The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover's COVID-19 vaccine candidate and will fund its development through licensure.

• 

  Clover Bio Dumps GSK Adjuvant Technology, Will Take Dynavax to Vaccine Dance

  2/1/2021

  China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.